Priors rates this Uncertain — 52 out of 100, updated weekly. It is genuinely uncertain. On the claim that intrathecal immunoglobulin synthesis induced by tofersen is manageable and does not require permanent treatment discontinuation in the majority of patients, its four-agent AI review panel weighs 19 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Antisense Oligonucleotide Gene Silencing in Amyotrophic Lateral Sclerosis with SOD1 Mutation review.